These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26451772)

  • 1. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
    Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
    Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel Bcr-Abl
    Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
    Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker.
    Pan X; Dong J; Shi Y; Shao R; Wei F; Wang J; Zhang J
    Org Biomol Chem; 2015 Jul; 13(25):7050-66. PubMed ID: 26052668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib.
    Pan X; Dong J; Shao R; Su P; Shi Y; Wang J; He L
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4164-8. PubMed ID: 26298495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel Bcr-Abl
    Pan X; Liu N; Zhang Q; Wang K; Li Y; Shan Y; Li Z; Zhang J
    Bioorg Med Chem; 2021 Oct; 48():116398. PubMed ID: 34547714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents.
    Dong J; Pan X; Wang J; Su P; Zhang L; Wei F; Zhang J
    Eur J Med Chem; 2015 Aug; 101():780-9. PubMed ID: 26231079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
    Pan X; Wang F; Zhang Y; Gao H; Hu Z; Wang S; Zhang J
    Bioorg Med Chem; 2013 May; 21(9):2527-34. PubMed ID: 23538233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
    Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
    Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
    Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Candidate Containing an (
    Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H
    J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl
    Lu X; Zhang Z; Ren X; Wang D; Ding K
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):331-336. PubMed ID: 28260399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
    Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
    J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
    Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-((3-amino-
    El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.